Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer’s disease
dc.contributor.author | Vangavaragu, Jhansi Rani | |
dc.contributor.author | Koteswara Rao, Valasani | |
dc.contributor.author | Gan, Xueqi | |
dc.contributor.author | Yan, Shirley ShiDu | |
dc.date.accessioned | 2017-06-12T18:57:38Z | |
dc.date.available | 2017-06-12T18:57:38Z | |
dc.date.issued | 2014-04-09 | |
dc.identifier.citation | Vangavaragu, J. R., Valasani, K. R., Gan, X., & Yan, S. S. (2014). Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 76, 506–516. http://doi.org/10.1016/j.ejmech.2014.02.046 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/24469 | |
dc.description.abstract | Amyloid-β (Aβ), a neurotoxic peptide, is linked to the onset of Alzheimer’s disease (AD). Increased Aβ content within neuronal cell mitochondria is a pathological feature in both human and mouse models with AD. This accumulation of Aβ within the mitochondrial landscape perpetuates increased free radical production and activation of the apoptotic pathway. Human Presequence Protease (hPreP) is responsible for the degradation of mitochondrial amyloid-β peptide in human neuronal cells, and is thus an attractive target to increase the proteolysis of Aβ. Therefore, it offers a potential target for Alzheimer’s drug design, by identifying potential activators of hPreP. We applied structure-based drug design, combined with experimental methodologies to investigate the ability of various compounds to enhance hPreP proteolytic activity. Compounds 3c & 4c enhanced hPreP-mediated proteolysis of Aβ (1–42), pF1β (2–54) and fluorogenic-substrate V. These results suggest that activation of hPreP by small benzimidazole derivatives provide a promising avenue for AD treatment. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 4.0 (CC BY-NC-ND 4.0), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Amyloid beta | en_US |
dc.subject | Alzheimer’s disease | en_US |
dc.subject | Enzyme activators | en_US |
dc.subject | Benzimidazole derivatives | en_US |
dc.subject | hPreP | en_US |
dc.title | Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer’s disease | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Vangavaragu, Jhansi Rani | |
kusw.kuauthor | Valasani, Koteswara Rao | |
kusw.kuauthor | Gan, Xueqi | |
kusw.kuauthor | Yan, Shirley ShiDu | |
kusw.kudepartment | Higuchi Biosciences Center | en_US |
dc.identifier.doi | 10.1016/j.ejmech.2014.02.046 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC4381964 | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 4.0 (CC BY-NC-ND 4.0), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.